Home › Trials › NCT06807268

Abrocitinib treatment for children 6 to under 12 with moderate-to-severe eczema

A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Phase 3 Interventional Pfizer · NCT06807268

We will test whether the medicine abrocitinib helps children aged 6 to under 12 with moderate-to-severe eczema and is safe.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment150 (estimated)
Ages6 Years to 11 Years
SexAll
SponsorPfizer Industry-sponsored
Drugs / interventionsabrocitinib
Locations41 sites (Birmingham, Alabama and 40 other locations)
Trial IDNCT06807268 on ClinicalTrials.gov

What this trial studies

Children who meet the entry criteria are randomly assigned to receive either abrocitinib or a matching placebo for 16 weeks, with the whole study lasting about 24 weeks. Caregivers and participants complete electronic diaries and questionnaires and wear a wrist device to measure scratching; clinic visits include physical exams, laboratory tests, and vital signs. Eligible participants have chronic moderate-to-severe atopic dermatitis with prior inadequate response to topical therapy and must weigh at least 15 kg. The study is placebo-controlled and double-arm to compare symptom and safety outcomes between the drug and placebo groups.

Who should consider this trial

Good fit: Ideal candidates are children aged 6 to under 12 years with chronic moderate-to-severe atopic dermatitis (BSA ≥10%, vIGA ≥3, EASI ≥16, WI-NRS ≥4), weight ≥15 kg, and a history of inadequate response to topical therapies.

Not a fit: Children with mild eczema, those outside the 6 to under 12 age range, or those with contraindications to JAK inhibitors or other disqualifying medical conditions are unlikely to benefit from joining this study.

Why it matters

Potential benefit: If successful, abrocitinib could reduce itching and skin inflammation in children 6–11 and offer a new systemic treatment option for moderate-to-severe eczema.

How similar studies have performed: Abrocitinib has shown efficacy and acceptable safety in randomized trials of adolescents and adults with moderate-to-severe atopic dermatitis, though data in 6–11-year-olds are more limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria Children aged 6 to \<12 years at the time of informed consent/assent.

• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

Disease Characteristics:

Participants who meet all of the following AD criteria:

* A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria\[19\]; and
* A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
* Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy

Other Inclusion Criteria:

Body weight ≥15 kg

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

Have any of the following medical conditions:

* Infections:

  * Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
  * History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
  * Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
  * Infection with HIV, hepatitis B, and/or hepatitis C
  * Evidence of active TB or inadequately treated latent TB.
* Skin Conditions:

  \- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
* Other Conditions:

  * Documented history of skeletal dysplasia.
  * Documented history of retinal detachment.
  * History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
  * Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
  * Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
  * Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

Prior/Concomitant Therapy:

Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.

Prior/Concurrent Clinical Study Experience:

Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

Where this trial is running

Birmingham, Alabama and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions EczemaDermatitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.